Professor Michael Shlipak, U.S.
Associate Chief of Medicine for Research Development at SFVAHCS, Scientific Director, Kidney Health Research Collaborative at UCSF, and Professor of Medicine, Epidemiology & Biostatistics at UCSF.Â
CKD diagnosis and staging: An update from the 2024 KDIGO guidelines
Chronic kidney disease (CKD) continues to pose a significant global health burden. The 2024 KDIGO Clinical Practice Guideline on the Evaluation and Management of CKD has important new recommendations for CKD detection, staging, risk assessment and treatment. The guidance has greatly expanded the populations who should be tested to detect CKD, and has expanded recommendations for incorporating both creatinine and cystatin C into glomerular filtration rate (GFR) assessment. Additionally, urine albumin monitoring has a greater role in determining CKD treatment decisions, and important new risk assessment tools are recommended for determining patients’ risk of both cardiovascular diseases and kidney failure. This lecture will provide an overview of these key advances in CKD diagnosis and management.
2025-11-19